Medical and Hospital News
INTERN DAILY
Pharma giant AstraZeneca takes China probes 'very seriously'
Reuters Events SMR and Advanced Reactor 2025
Pharma giant AstraZeneca takes China probes 'very seriously'
by AFP Staff Writers
London (AFP) Nov 12, 2024

British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss.

"We take the matters in China very seriously," chief executive Pascal Soriot said in a statement contained in the group's latest earnings release that revealed a small rise in net profit.

"If requested we will fully cooperate with the authorities. We remain committed to delivering innovative life-changing medicines to patients in China," he added.

The group last week confirmed Leon Wang, president of AstraZeneca China, had been detained.

China is a key market for AstraZeneca, developer of a Covid-19 jab widely administered throughout the world during the coronavirus pandemic.

AstraZeneca on Tuesday noted that China accounted for about 12 percent of its global revenues in the third quarter. Sales in the country jumped 15 percent in the July-September period.

"The company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca employees," the drugs giant added in the latest statement.

"To the best of the company's knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches."

AstraZeneca said it "has not received any notification that it is itself under investigation".

The probes involved five current and former employees of the firm -- all with Chinese citizenship -- which are being led by authorities in the southern city of Shenzhen, according to Bloomberg.

One investigation related to the firm's collection of patient data, which authorities suspect may have breached Chinese privacy laws, the financial newswire also reported, citing people with knowledge of the situation.

Another probe related to imports of a liver cancer drug that had not been approved in mainland China, according to Bloomberg.

UK-headquartered AstraZeneca has 90,000 employees globally.

Multinationals have faced an increasingly-difficult business environment in China in recent years, industry groups say, citing a lack of transparency on data laws and prolonged detentions of employees.

- US investment -

AstraZeneca on Tuesday added that profit after tax rose four percent in the third quarter to $1.4 billion from a year earlier.

Total revenue jumped 18 percent to $13.6 billion, "reflecting the increasing demand for our medicines across oncology, biopharmaceuticals and rare disease", said Soriot.

The group also announced $2-billion of new investment in its main market, the United States.

Shares in AstraZeneca were down 1.3 percent in midday deals on London's top-tier FTSE 100 index, which was trading one percent lower overall.

Its shares fell sharply when reports of Wang's detention emerged earlier this month, wiping billions of dollars off its valuation.

AstraZeneca's profits "upgrade puts the Chinese probe in perspective", noted Derren Nathan, head of equity research at Hargreaves Lansdown.

burs-bcp/ajb/db

Related Links
Hospital and Medical News at InternDaily.com

Subscribe Free To Our Daily Newsletters
Tweet

RELATED CONTENT
The following news reports may link to other Space Media Network websites.
INTERN DAILY
WHO chief says Lebanon health system 'struggling to cope'
Geneva (AFP) Oct 2, 2024
The World Health Organization chief warned Tuesday that Lebanon's health system was struggling to keep up, after Israel escalated airstrikes and launched ground raids into the country. "The death toll in Lebanon is rising, and hospitals are overwhelmed with the influx of injured patients," Tedros Adhanom Ghebreyesus warned on X. "The health system has been weakened by successive crises and is struggling to cope with the immense needs," he said, adding that WHO was scaling up its response. Is ... read more

INTERN DAILY
Cuba says arrests made over hurricane blackout protests; 2 quakes jolt island

Climate crisis worsening already 'hellish' refugee situation: UN

Fukushima nuclear debris arrives at lab after secret journey

Spain PM says flood disaster debate must follow recovery

INTERN DAILY
Successful demo showcases BAE Systems' next-gen M-Code GNSS technology

BeiDou remote sensing experiment enhances ecological monitoring in Yellow River

Aerodata earns EASA certification for GPS anti-jamming and anti-spoofing tech

Axient secures contract for Resilient GPS Constellation under USSF Initiative

INTERN DAILY
Chimpanzees show improved performance on difficult computer tasks with an audience

New findings on Denisovans reveal their role in shaping early human genetics

Memories extend beyond the brain in new NYU study

Human culture's distinctiveness lies in its open-ended nature

INTERN DAILY
Fifty years of data reveal significant African elephant population declines

Bees help tackle elephant-human conflict in Kenya

New tools give researchers hope for fungus-ravaged US bats

Critically endangered Sumatran elephant calf born in Indonesia

INTERN DAILY
Spread of dengue fever in Bangladesh worries medics

Climate shifts and urbanisation drive Nepal dengue surge

Covid lessons learned? UN summit mulls plan for healthy planet, and humans

WHO launches plan to rein in 'alarming' dengue spread

INTERN DAILY
Chinese slimmers trim down at weight-loss camps

China's Myanmar consulate hit with explosive device: Junta chief to visit China next month

China to almost double support for unfinished housing projects

Myanmar junta chief to travel to China next month: sources close to military

INTERN DAILY
El Salvador troops target gangs in large-scale operation

Hungary's Orban says corks will pop if Trump wins US election

INTERN DAILY
Subscribe Free To Our Daily Newsletters




The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.